Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-266-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$240,000.00
Profitability
Miscellaneous
Employees29
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.08. View Sunesis Pharmaceuticals' Earnings History.
When is Sunesis Pharmaceuticals' next earnings date?
What price target have analysts set for SNSS?
2 brokers have issued 1 year price objectives for Sunesis Pharmaceuticals' shares. Their forecasts range from $0.50 to $6.00. On average, they anticipate Sunesis Pharmaceuticals' share price to reach $3.25 in the next year. This suggests a possible upside of 203.7% from the stock's current price. View Analyst Price Targets for Sunesis Pharmaceuticals.
What is the consensus analysts' recommendation for Sunesis Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sunesis Pharmaceuticals.
Has Sunesis Pharmaceuticals been receiving favorable news coverage?
News coverage about SNSS stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sunesis Pharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the company's share price in the near term.
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include XBiotech (XBIT), Zynerba Pharmaceuticals (ZYNE), Kindred Biosciences (KIN), Merus (MRUS), resTORbio (TORC), Dova Pharmaceuticals (DOVA), Geron (GERN), ImmunoGen (IMGN), Kadmon (KDMN), Immune Design (IMDZ), Karyopharm Therapeutics (KPTI), Molecular Templates (MTEM), Athersys (ATHX), Hookipa Pharma (HOOK) and Aduro BioTech (ADRO).
What other stocks do shareholders of Sunesis Pharmaceuticals own?
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)
- Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)
- Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)
- Mr. Gene C. Jamieson, VP of Technical Operations
- Dr. Judith A. Fox, Chief Scientific Officer
Who are Sunesis Pharmaceuticals' major shareholders?
Sunesis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Aisling Capital Management LP (10.48%), Samsara BioCapital LLC (5.17%), Wells Fargo & Company MN (1.39%), Fosun International Ltd (1.07%), BlackRock Inc. (0.32%) and Northern Trust Corp (0.15%). Company insiders that own Sunesis Pharmaceuticals stock include Dayton Misfeldt, Mpm Oncology Impact Management and William P Quinn. View Institutional Ownership Trends for Sunesis Pharmaceuticals.
Which institutional investors are selling Sunesis Pharmaceuticals stock?
Which institutional investors are buying Sunesis Pharmaceuticals stock?
SNSS stock was acquired by a variety of institutional investors in the last quarter, including Aisling Capital Management LP, Samsara BioCapital LLC, Wells Fargo & Company MN, Fosun International Ltd, Renaissance Technologies LLC, BlackRock Inc., Northern Trust Corp and Algert Global LLC. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Dayton Misfeldt, Mpm Oncology Impact Management and William P Quinn. View Insider Buying and Selling for Sunesis Pharmaceuticals.
How do I buy shares of Sunesis Pharmaceuticals?
Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
One share of SNSS stock can currently be purchased for approximately $1.07.
How big of a company is Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals has a market capitalization of $77.60 million and generates $240,000.00 in revenue each year. The biopharmaceutical company earns $-26,610,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Sunesis Pharmaceuticals employs 29 workers across the globe.
What is Sunesis Pharmaceuticals' official website?
How can I contact Sunesis Pharmaceuticals?
Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]
MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days.
